1 Wilson BA, Salyers AA. Bacterial pathogenesis: a molecular approach. Washington, DC: ASM Press; 2011.
2 John E. Bennett RD, Martin J. Blaser Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 8th Edition 28 Aug 2014.
3 Cundell DR, Weiser JN, Shen J, Young A, Tuomanen EI. Relationship between colonial morphology and adherence of Streptococcus pneumoniae. Infect Immun. 1995;63(3):757–61.
4 Moscoso M, Garcia E, Lopez R. Pneumococcal biofilms. Int Microbiol. 2009;12(2):77–85.
5 Sousa A, Perez-Rodriguez MT, Nodar A, Martinez-Lamas L, Vasallo FJ, Alvarez-Fernandez M, et al. Clinical and microbiological characteristics of unusual manifestations of invasive pneumococcal disease. Enferm Infecc Microbiol Clin. 2017;22(17):30164–7.
6 Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG, Jr., Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009;169(5):463–73.
7 Daudin M, Tattevin P, Lelong B, Flecher E, Lavoue S, Piau C, et al. Characteristics and prognosis of pneumococcal endocarditis: a case-control study. Clin Microbiol Infect. 2016;22(6):26.
8 Mansur AJ, Grinberg M, da Luz PL, Bellotti G. The complications of infective endocarditis. A reappraisal in the 1980s. Arch Intern Med. 1992;152(12):2428–32.
9 Pigrau C, Almirante B, Flores X, Falco V, Rodriguez D, Gasser I, et al. Spontaneous pyogenic vertebral osteomyelitis and endocarditis: incidence, risk factors, and outcome. Am J Med. 2005;118(11).
10 Siddiq DM, Musher DM, Darouiche RO. Spinal and paraspinal pneumococcal infections-a review. Eur J Clin Microbiol Infect Dis. 2014;33(4):517–27.
11 Kutas LM, Duggan JM, Kauffman CA. Pneumococcal vertebral osteomyelitis. Clin Infect Dis. 1995;20(2):286–90.
12 Backhaus E, Berg S, Andersson R, Ockborn G, Malmstrom P, Dahl M, et al. Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infect Dis. 2016;16(367):016–1648.
13 Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41.
14 BAG Bulletin, 40/2017. Oktober 2017.
15 Empfehlungen zur Verhinderung von invasiven Pneumokokkenerkrankungen bei Risikogruppen. BAG Bulletin. 2014;8:129–41.